Study guide

5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury

DABT: Diplomate of the American Board of Toxicology Exam

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Study Design Fundamentals

1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration

2 Dose Selection, Controls & Biostatistics in Toxicology

2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

3 Study Execution, GLP Compliance & Quality Assurance

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections

4 Executing In Vivo, In Vitro, In Silico & Field Studies

4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization

5 Clinical Pathology & Toxicologic Pathology

5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation

6 Specialized Toxicological Study Endpoints

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology

7 Toxicokinetics & Biotransformation

7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification

8 Cellular Mechanisms of Toxicity & Organ Pathogenesis

8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

9 Hazard Identification & Evidence Integration

9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses

10 Mode of Action, AOPs & Non-Cancer Endpoints

10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects

11 Exposure Assessment Methodologies & Quantification

11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

12 Quantitative Dose-Response Principles & Point of Departure Derivation

12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose

13 Health-Based Guidance Value Derivation & Uncertainty Factors

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)

14 Risk Characterization for Non-Cancer & Cancer Health Effects

14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization

15 Risk Management, Occupational Exposure Limits & Environmental Standards

15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations

16 Regulatory Frameworks & Product Stewardship

16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH

17 Clinical Toxicology & Medical Management of Poisoning

17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies

18 Environmental, Ecological & Public Health Toxicology

18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation

5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury

Key Takeaways Explain This Topic AI

ALT, AST, SDH, and GLDH are leakage enzymes of hepatocellular (and, for AST, muscle or erythrocyte) injury; ALP and GGT more often rise by induction in cholestasis or after certain enzyme-inducing treatments.

Centrilobular necrosis typically lights up ALT/AST/GLDH/SDH first; biliary hyperplasia and cholestasis typically light up ALP, GGT, and bilirubin—do not treat “liver enzymes” as one interchangeable pool.

BUN and creatinine are late, imperfect GFR markers; SDMA and cystatin C can detect GFR decline with less muscle-mass dependence but remain adjuncts to urinalysis, kidney weights, and histopathology.

CK is the muscle leakage enzyme of choice; pair it with AST and ALT so injection-site or restraint injury is not reported as hepatotoxicity.

Fasting, in-vitro hemolysis, and age (especially bone ALP in juveniles) routinely mimic or mask toxicant effects; interpret chemistry against concurrent, similarly handled controls.

Last updated: September 2026

Why chemistry is more than starred means

Domain I.C.2 continues from the CBC into clinical chemistry : enzymes, metabolites, electrolytes, proteins, and lipids that report organ injury or function while the animal is still alive. Independent ExamFinch material here trains you to name the pattern (hepatocellular leakage, cholestasis, decreased GFR, muscle injury, artifact) before you name a target organ. A table of “significantly increased liver enzymes” that never says which enzymes, and never mentions creatine kinase, histopathology, or sample quality, is not an interpretation.

This section is original teaching. It does not reproduce American Board of Toxicology sample items. The skill is the same one you need on novel stems: match the analyte family to the biology, then confirm or refute the story with concurrent controls and morphology.

Leakage versus induction enzymes

Leakage enzymes sit in cytosol or mitochondria and spill when membranes fail. The hepatocellular set is alanine aminotransferase (ALT) , aspartate aminotransferase (AST) , sorbitol dehydrogenase (SDH) (iditol dehydrogenase), and glutamate dehydrogenase (GLDH) . Creatine kinase (CK) is the muscle counterpart. Magnitude roughly tracks the amount of injured tissue and the enzyme’s plasma half-life. A large ALT spike with necrosis can still be fully reversible if surviving hepatocytes regenerate and the insult stops.

Induction enzymes increase because the cell synthesizes more protein . Classically alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) rise in cholestasis or after certain microsomal enzyme-inducing treatments. ALP also comes from bone (young growing animals) and, in dogs , a corticosteroid-induced isoform . High ALP in a six-week-old puppy or a rapidly growing rat is not automatically a biliary toxicant. Treating ALP as “the liver leakage enzyme” is the category error this section exists to prevent.

Half-life matters operationally. SDH is labile —delays between draw and assay lose activity. GLDH is more stable and is widely used in rodents as a relatively specific mitochondrial hepatocellular marker. AST is in liver, muscle, and erythrocytes, so hemolyzed tubes and muscle trauma both inflate it. Use AST with ALT and CK, not as a solo “liver test.”

Hepatocellular injury: ALT, AST, SDH, GLDH

ALT is the workhorse hepatocellular leakage enzyme in dog, cat, rat, and primate . Skeletal muscle contains some ALT in several species, so a muscle-injury pattern can lift ALT, but in the usual laboratory species a large ALT rise with a quiet CK still points at liver.

AST is less tissue-specific. SDH is more liver-specific in several species and is valuable when ALT is uninformative, provided the laboratory assays it promptly. GLDH reports mitochondrial hepatocellular injury and pairs well with histologic centrilobular necrosis —zone 3 is cytochrome-rich and relatively hypoxic, so many bioactivated hepatotoxicants (classic teaching examples include carbon tetrachloride-type injury) declare themselves there.

Do not rank “which single enzyme proves hepatotoxicity” as a parlor game. The coherent package is which leakage enzymes moved , whether CK moved , whether bilirubin and ALP moved , and what the liver looks like .

Cholestasis: ALP, GGT, bilirubin

ALP , GGT , and total/conjugated bilirubin describe cholestasis and biliary induction more than pure leakage necrosis. Biliary hyperplasia , bile-duct injury, canalicular obstruction, and some enzyme inducers raise ALP/GGT. Bilirubin rises when conjugation or excretion fails or when hemolysis overloads hepatic uptake; fractionate when you can (conjugated versus unconjugated) to separate excretion failure from hemolysis.

A chemical that causes centrilobular necrosis typically lights up ALT/AST/GLDH/SDH first; bilirubin and ALP may stay modest until injury is extensive. A chemical that causes bile-duct hyperplasia or cholestasis lights up ALP/GGT/bilirubin , with ALT milder unless hepatocytes are also dying. Those two patterns are not interchangeable “liver enzyme” events.

Kidney: BUN and creatinine versus SDMA and cystatin C

Blood urea nitrogen (BUN) (urea) rises when glomerular filtration rate (GFR) falls, but also with high protein catabolism , gastrointestinal hemorrhage (absorbed nitrogen), dehydration , and high-protein diets. Creatinine tracks GFR more cleanly but depends on muscle mass ; cachectic animals under-generate creatinine, masking GFR loss. Prerenal azotemia (dehydration, shock) raises BUN ± creatinine with concentrated urine and often no primary renal histologic lesion.

Symmetric dimethylarginine (SDMA) and cystatin C are low-molecular-weight markers that can detect GFR decline with less muscle-mass dependence than creatinine. In regulatory packages they are still adjuncts . BUN, creatinine, urinalysis, kidney weights, and histopathology remain the core. Do not discard a creatinine increase because SDMA was not measured, and do not call SDMA a histopathology substitute. Section 5.3 continues this story with urinary KIM-1 , NGAL , and clusterin , which report tubular injury rather than GFR.

Muscle, electrolytes, glucose, lipids, proteins

CK is the muscle leakage enzyme of choice. AST rises with muscle too. Injection-site injury, restraint in NHP, intramuscular dosing, and some convulsive test articles raise CK. Pair CK with AST/ALT to avoid calling muscle leakage hepatotoxicity. Cardiac muscle injury is better supported later with cardiac troponins (section 5.3) plus heart weights and histology; CK alone does not localize heart versus skeletal muscle.

Electrolytes (sodium, potassium, chloride, bicarbonate) catch gastrointestinal loss, renal tubular dysfunction, mineralocorticoid effects, and artifact. Hemolysis raises potassium in several species. Glucose : fasting lowers it; stress and glucocorticoids raise it. Lipids : fasting, diet, cholestasis (cholesterol), and PPAR-type pharmacology. Proteins : albumin falls with hepatic synthetic failure, gastrointestinal or renal loss, or inflammation (negative acute-phase); globulins rise with inflammation. The albumin-to-globulin (A/G) ratio helps classify those patterns.

Confounders: fasting, hemolysis, age

Fasting (often overnight before a terminal bleed) drops glucose, can drop triglycerides, and may slightly change bilirubin and ALP. Compare fasted to fasted. Mixing unfasted interim bleeds with fasted terminal bleeds manufactures chemistry “findings.”

Hemolysis in the tube raises potassium, AST, lactate dehydrogenase, phosphate, and can interfere optically with many assays. Mark hemolyzed samples. Do not invent a hepatocellular AST story from a red serum when ALT and GLDH are quiet and CK is unhelpful.

Age : bone ALP is high in juveniles; young rats have different protein and enzyme baselines; geriatric rats add chronic progressive nephropathy and background liver change. Always use concurrent age-matched controls. Historical ranges help you sanity-check; they do not replace the concurrent control group.

Pattern recognition: centrilobular necrosis versus biliary hyperplasia

Clinicopathologic pattern Typical chemistry Histopathology you expect to confirm

Acute hepatocellular leakage ALT, AST, SDH, and/or GLDH increased; ALP/bilirubin normal or lagging Centrilobular (or other zonal) degeneration/necrosis

Cholestatic / biliary induction ALP and/or GGT increased; bilirubin increased when excretion fails Bile-duct hyperplasia, cholestasis, periportal inflammation or fibrosis

Mixed hepatocellular and biliary Both leakage and induction enzymes up Hepatocellular injury plus a biliary reaction

Muscle CK dominant; AST up; ALT milder Skeletal or cardiac muscle; injection site

Decreased GFR BUN ± creatinine up; possible hyperphosphatemia Glomerular/tubular/interstitial change—or prerenal (no primary renal lesion)

Scenario

High-dose dogs have ALT eight times concurrent controls, GLDH up, ALP 1.2 times control, bilirubin unchanged, CK unchanged. Histology shows centrilobular hepatocellular necrosis. That is hepatocellular leakage, not a primary cholestatic story. Writing “liver function tests are up” without naming the pattern would miss the point of I.C.2.

A different cohort has ALP six times control, GGT up, bilirubin up, ALT 1.5 times control, and histology showing bile-duct hyperplasia without necrosis. That is a biliary/cholestatic pattern. Treating the two cohorts as interchangeable because both involve the liver is the error.

A third cohort, NHP this time, has AST and CK high, ALT barely moved, and no hepatic necrosis. The chemistry is muscle (restraint or injection), not a silent hepatotoxicant.

Traps

Calling ALP a hepatocellular leakage enzyme.

Ignoring CK when AST is high.

Using unfasted historical ranges on fasted terminal bleeds.

Equating any BUN rise with tubular necrosis.

Reading hemolyzed samples as disease.

Treating SDMA as a required OECD 408 replacement for creatinine rather than an adjunct GFR marker.